Mass spectrometry in clinical proteomics - From the present to the future

Proteomics - Clinical Applications

Volumn 3, Issue 1, 2009, Pages 6-17

  Palmblad, Magnus ^a   Tiss, Ali ^b   Cramer, Rainer ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF READING   (United Kingdom)

Author keywords

Clinical proteomics; Diagnostics; Mass spectrometry; Profiling; Screening

Indexed keywords

PROTEASOME;

BODY FLUID; BREAST CANCER; CANCER DIAGNOSIS; CANCER RESEARCH; DISEASE MARKER; EARLY DIAGNOSIS; GEL ELECTROPHORESIS; HIGH THROUGHPUT SCREENING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MEDICAL RESEARCH; OVARY CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PURIFICATION; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY;

EID: 65549148245     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200800090     Document Type: Review

References (173)

1. Jellum, E., Stokke, O., Eldjarn, L., Application of gas chromatography, mass spectrometry, and computer methods in clinical biochemistry. Anal. Chem. 1973, 46, 1099-1106.
2. Lawson, A. M., The scope of mass spectrometry in clinical chemistry. Clin. Chem. 1975, 21, 803-824.
3. Mizuno, T., Abe, N., Teshima, H., Yamauchi, E. et al., Application of a gas chromatography mass spectrometry computer system for clinical diagnosis. Biomed. Mass Spectrom. 1981, 8, 593-597.
4. Chace, D. H., Millington, D. S., Terada, N., Kahler, S. G. et al., Rapid diagnosis of phenylketonuria by quantitative analysis for phenylalanine and tyrosine in neonatal blood spots by tandem mass spectrometry. Clin. Chem. 1993, 39, 66-71.
5. Lowes, S., Rose, M. E., Simple and unambiguous method for identifying urinary acylcarnitines using gas chromatography-mass spectrometry. Analyst 1990, 115, 511-516.
6. Millington, D. S., Kodo, N., Norwood, D. L., Roe, C. R., Tandem mass spectrometry: A new method for acylcarnitine profiling with potential for neonatal screening for inborn errors of metabolism. J. Inherit. Metab. Dis. 1990, 13, 321-324.
7. Sweetman, L., Newborn screening by tandem mass spectrometry (MS-MS). Clin. Chem. 1996, 42, 345-346.
8. Downing, M., Pollitt, R., Newborn bloodspot screening in the UK-past, present and future. Ann. Clin. Biochem. 2008, 45, 11-17.
9. Frazier, D. M., Millington, D. S., McCandless, S. E., Koeberl, D. D. et al., The tandem mass spectrometry newborn screening experience in North Carolina: 1997-2005. J. Inherit. Metab. Dis. 2006, 29, 76-85.
10. Schulze, A., Lindner, M., Kohlmuller, D., Olgemoller, K. et al., Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: Results, outcome, and implications. Pediatrics 2003, 111, 1399-1406.
11. Turecek, F., Scott, C. R., Gelb, M. H., Tandem mass spectrometry in the detection of inborn errors of metabolism for newborn screening. Methods Mol. Biol. 2007, 359, 143-157.
12. Wilcken, B., Wiley, V., Newborn screening. Pathology 2008, 40, 104-115.
13. Wilcken, B., Wiley, V., Hammond, J., Carpenter, K., Screening newborns for inborn errors of metabolism by tandem mass spectrometry. N. Engl. J. Med. 2003, 348, 2304-2312.
14. Yoon, H. R., Lee, K. R., Kang, S., Lee, D. H. et al., Screening of newborns and high-risk group of children for inborn metabolic disorders using tandem mass spectrometry in South Korea: A three-year report. Clin. Chim. Acta. 2005, 354, 167-180.
15. Whiteaker, J. R., Zhang, H., Zhao, L., Wang, P. et al., Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. J. Proteome Res. 2007, 6, 3962-3975.
16. Gramolini, A., Peterman, S., Kislinger, T., Mass spectrometry-based proteomics: A useful tool for biomarker discovery? Clin. Pharmacol. Ther. 2008, 83, 758-760.
17. Dubois, F., Knochenmuss, R., Zenobi, R., Brunelle, A. et al., A comparison between ion-to-photon and microchannel plate detectors. Rapid Commun. Mass Spectrom. 1999, 13, 786-791.
18. Delahunty, C. M., Yates, J. R., IIIrd, MudPIT: Multidimensional protein identification technology. Biotechniques 2007, 43, 563, 565, 567 passim.
19. Liu, H., Lin, D., Yates, J. R., IIIrd, Multidimensional separations for protein/peptide analysis in the post-genomic era. Biotechniques 2002, 32, 898, 900, 902 passim.
20. Motoyama, A., Venable, J. D., Ruse, C. I., Yates, J. R., IIIrd, Automated ultra-high-pressure multidimensional protein identification technology (UHP-MudPIT) for improved peptide identification of proteomic samples. Anal. Chem. 2006, 78, 5109-5118.
21. Gauss, C., Kalkum, M., Lowe, M., Lehrach, H., Klose, J., Analysis of the mouse proteome. (I) Brain proteins: Separation by two-dimensional electrophoresis and identification by mass spectrometry and genetic variation. Electrophoresis 1999, 20, 575-600.
22. Page, M. J., Amess, B., Townsend, R. R., Parekh, R. et al., Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties. Proc. Natl. Acad. Sci. USA 1999, 96, 12589-12594.
23. Somiari, R. I., Somiari, S., Russell, S., Shriver, C. D., Proteomics of breast carcinoma. J. Chromatogr., B: Anal. Technol. Biomed. Life Sci. 2005, 815, 215-225.
24. Wulfkuhle, J. D., Sgroi, D. C., Krutzsch, H., McLean, K. et al., Proteomics of human breast ductal carcinoma in situ. Cancer Res. 2002, 62, 6740-6749.
25. Vissers, J. P., Recent developments in microcolumn liquid chromatography. J. Chromatogr., A 1999, 856, 117-143.
26. Ericson, C., Phung, Q. T., Horn, D. M., Peters, E. C. et al., An automated noncontact deposition interface for liquid chromatography matrix-assisted laser desorption/ionization mass spectrometry. Anal. Chem. 2003, 75, 2309-2315.
27. Mirgorodskaya, E., Braeuer, C., Fucini, P., Lehrach, H., Gobom, J., Nanoflow liquid chromatography coupled to matrix-assisted laser desorption/ionization mass spectrometry: Sample preparation, data analysis, and application to the analysis of complex peptide mixtures. Proteomics 2005, 5, 399-408.
28. Pieper, R., Su, Q., Gatlin, C. L., Huang, S. T. et al., Multicomponent immunoaffinity subtraction chromatography: An innovative step towards a comprehensive survey of the human plasma proteome. Proteomics 2003, 3, 422-432.
29. Alban, A., David, S. O., Bjorkesten, L., Andersson, C. et al., A novel experimental design for comparative two-dimensional gel analysis: Two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 2003, 3, 36-44.
30. Ong, S. E., Blagoev, B., Kratchmarova, I., Kristensen, D. B. et al., Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics 2002, 1, 376-386.
31. Gerber, S. A., Rush, J., Stemman, O., Kirschner, M. W., Gygi, S. P., Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc. Natl. Acad. Sci. USA 2003, 100, 6940-6945.
32. Gygi, S. P., Rist, B., Gerber, S. A., Turecek, F. et al., Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 1999, 17, 994-999.
33. Ross, P., Dey, S., Pillai, S., Daniels, S. et al., 54th ASMS Conference on Mass Spectrometry, ASMS, Seattle, WA 2006.
34. Ross, P. L., Huang, Y. N., Marchese, J. N., Williamson, B. et al., Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics 2004, 3, 1154-1169.
35. Turck, C. W., Falick, A. M., Kowalak, J. A., Lane, W. S. et al., The association of biomolecular resource facilities proteomics research group 2006 study: Relative protein quantitation. Mol. Cell. Proteomics 2007, 6, 1291-1298.
36. Bergstrom, S. K., Dahlin, A. P., Ramstrom, M., Andersson, M. et al., A simplified multidimensional approach for analysis of complex biological samples: On-line LC-CE-MS. Analyst 2006, 131, 791-798.
37. Evans, C. R., Jorgenson, J. W., Multidimensional LC-LC and LC-CE for high-resolution separations of biological molecules. Anal. Bioanal. Chem. 2004, 378, 1952-1961.
38. Zürbig, P., Mischak, H., Capillary electrophoresis coupled to mass spectrometry for biomarker discovery and diagnosis of kidney diseases. Contrib. Nephrol. 2008, 160, 107-126.
39. Sniehotta, M., Schiffer, E., Zürbig, P., Novak, J., Mischak, H., CE - a multifunctional application for clinical diagnosis. Electrophoresis 2007, 28, 1407-1417.
40. Vitzthum, F., Behrens, F., Anderson, N. L., Shaw, J. H., Proteomics: From basic research to diagnostic application. A review of requirements and needs. J. Proteome Res. 2005, 4, 1086-1097.
41. Anderson, L., Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J. Physiol. 2005, 563, 23-60.
42. Adkins, J. N., Monroe, M. E., Auberry, K. J., Shen, Y. et al., A proteomic study of the HUPO Plasma Proteome Project's pilot samples using an accurate mass and time tag strategy. Proteomics 2005, 5, 3454-3466.
43. Anderson, N. L., Anderson, N. G., The human plasma proteome: History, character, and diagnostic prospects. Mol. Cell. Proteomics 2002, 1, 845-867.
44. Petricoin, E. F., Fishman, D. A., Conrads, T. P., Veenstra, T. D., Liotta, L. A., Lessons from Kitty Hawk: From feasibility to routine clinical use for the field of proteomic pattern diagnostics. Proteomics 2004, 4, 2357-2360.
45. Petricoin, E. F., Ardekani, A. M., Hitt, B. A., Levine, P. J. et al., Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359, 572-577.
46. Adam, B. L., Qu, Y., Davis, J. W., Ward, M. D. et al., Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 2002, 62, 3609-3614.
47. Li, J., Zhang, Z., Rosenzweig, J., Wang, Y. Y., Chan, D. W., Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin. Chem. 2002, 48, 1296-1304.
48. Villanueva, J., Philip, J., Entenberg, D., Chaparro, C. A. et al., Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal. Chem. 2004, 76, 1560-1570.
49. Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V. et al., Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003, 4, 437-450.
50. Petricoin, E. F., IIIrd, Ornstein, D. K., Paweletz, C. P., Ardekani, A. et al., Serum proteomic patterns for detection of prostate cancer. J. Natl. Cancer Inst. 2002, 94, 1576-1578.
51. Conrads, T. P., Fusaro, V. A., Ross, S., Johann, D. et al., High-resolution serum proteomic features for ovarian cancer detection. Endocr. Relat. Cancer 2004, 11, 163-178.
52. Ebert, M. P., Meuer, J., Wiemer, J. C., Schulz, H. U. et al., Identification of gastric cancer patients by serum protein profiling. J. Proteome Res. 2004, 3, 1261-1266.
53. Ornstein, D. K., Rayford, W., Fusaro, V. A., Conrads, T. P. et al., Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml. J. Urol. 2004, 172, 1302-1305.
54. Wright, G. L., Jr., SELDI proteinchip MS: A platform for biomarker discovery and cancer diagnosis. Expert Rev. Mol. Diagn. 2002, 2, 549-563.
55. Tang, N., Tornatore, P., Weinberger, S. R., Current developments in SELDI affinity technology. Mass Spectrom. Rev. 2004, 23, 34-44.
56. Hutchens, T. W., Yip, T. T., New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Commun. Mass Spectrom. 1993, 7, 576-580.
57. Weinberger, S. R., Morris, T. S., Pawlak, M., Recent trends in protein biochip technology. Pharmacogenomics 2000, 1, 395-416.
58. Veenstra, T. D., Prieto, D. A., Conrads, T. P., Proteomic patterns for early cancer detection. Drug Discovery Today 2004, 9, 889-897.
59. Tiss, A., Smith, C., Camuzeaux, S., Kabir, M. et al., Serum peptide profiling using MALDI mass spectrometry: Avoiding the pitfalls of coated magnetic beads using well-established ZipTip technology. Proteomics 2007, 7, 77-89.
60. Whiteaker, J. R., Zhang, H., Eng, J. K., Fang, R. et al., Head-to-head comparison of serum fractionation techniques. J. Proteome Res. 2007, 6, 828-836.
61. Cheng, A. J., Chen, L. C., Chien, K. Y., Chen, Y. J. et al., Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. Clin. Chem. 2005, 51, 2236-2244.
62. Nelsestuen, G. L., Zhang, Y., Martinez, M. B., Key, N. S. et al., Plasma protein profiling: Unique and stable features of individuals. Proteomics 2005, 5, 4012-4024.
63. Gillette, M. A., Mani, D. R., Carr, S. A., Place of pattern in proteomic biomarker discovery. J. Proteome Res. 2005, 4, 1143-1154.
64. Coombes, K. R., Morris, J. S., Hu, J., Edmonson, S. R., Baggerly, K. A., Serum proteomics profiling a young technology begins to mature. Nat. Biotechnol. 2005, 23, 291-292.
65. Diamandis, E. P., Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: Opportunities and potential limitations. Mol. Cell. Proteomics 2004, 3, 367-378.
66. Check, E., Proteomics and cancer: Running before we can walk? Nature 2004, 429, 496-497.
67. Ransohoff, D. F., Bias as a threat to the validity of cancer molecular-marker research. Nat. Rev. Cancer 2005, 5, 142-149.
68. Villanueva, J., Philip, J., Chaparro, C. A., Li, Y. et al., Correcting common errors in identifying cancer-specific serum peptide signatures. J. Proteome Res. 2005, 4, 1060-1072.
69. West-Nielsen, M., Hogdall, E. V., Marchiori, E., Hogdall, C. K. et al., Sample handling for mass spectrometric proteomic investigations of human sera. Anal. Chem. 2005, 77, 5114-5123.
70. West-Norager, M., Kelstrup, C. D., Schou, C., Hogdall, E. V. et al., Unravelling in vitro variables of major importance for the outcome of mass spectrometry-based serum proteomics. J. Chromatogr., B: Anal. Technol. Biomed. Life Sci. 2007, 847, 30-37.
71. Aresta, A., Calvano, C. D., Palmisano, F., Zambonin, C. G. et al., Impact of sample preparation in peptide/protein profiling in human serum by MALDI-TOF mass spectrometry. J. Pharm. Biomed. Anal. 2008, 46, 157-164.
72. Callesen, A. K., Vach, W., Jorgensen, P. E., Cold, S. et al., Reproducibility of mass spectrometry-based protein profiles for diagnosis of breast cancer across clinical studies: A systematic review. J. Proteome Res. 2008, 7, 1395-1402.
73. Callesen, A. K., Vach, W., Jorgensen, P. E., Cold, S. et al., Combined experimental and statistical strategy for mass spectrometry-based serum protein profiling for diagnosis of breast cancer: A case-control study. J. Proteome Res. 2008, 7, 1419-1426.
74. Parkin, D. M., Bray, F., Ferlay, J., Pisani, P., Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55, 74-108.
75. Coleman, M. P., Trends in breast cancer incidence, survival, and mortality. Lancet 2000, 356, 590-591.
76. Jemal, A., Siegel, R., Ward, E., Murray, T. et al., Cancer statistics, 2006. CA Cancer J. Clin. 2006, 56, 106-130.
77. Vlahou, A., Laronga, C., Wilson, L., Gregory, B. et al., A novel approach toward development of a rapid blood test for breast cancer. Clin. Breast Cancer 2003, 4, 203-209.
78. Becker, S., Cazares, L. H., Watson, P., Lynch, H. et al., Surfaced-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer. Ann. Surg. Oncol. 2004, 11, 907-914.
79. Hu, Y., Zhang, S., Yu, J., Liu, J., Zheng, S., SELDI-TOF-MS: The proteomics and bioinformatics approaches in the diagnosis of breast cancer. Breast 2005, 14, 250-255.
80. Caputo, E., Lombardi, M. L., Luongo, V., Moharram, R. et al., Peptide profiling in epithelial tumor plasma by the emerging proteomic techniques. J. Chromatogr., B: Anal. Technol. Biomed. Life Sci. 2005, 819, 59-66.
81. Mathelin, C., Cromer, A., Wendling, C., Tomasetto, C., Rio, M. C., Serum biomarkers for detection of breast cancers: A prospective study. Breast Cancer Res. Treat. 2006, 96, 83-90.
82. Mendrinos, S., Nolen, J. D., Styblo, T., Carlson, G. et al., Cytologic findings and protein expression profiles associated with ductal carcinoma of the breast in ductal lavage specimens using surface-enhanced laser desorption and ionization-time of flight mass spectrometry. Cancer 2005, 105, 178-183.
83. Paweletz, C. P., Trock, B., Pennanen, M., Tsangaris, T. et al., Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: Potential for new biomarkers to aid in the diagnosis of breast cancer. Dis. Markers 2001, 17, 301-307.
84. Sauter, E. R., Zhu, W., Fan, X. J., Wassell, R. P. et al., Proteomic analysis of nipple aspirate fluid to detect biologic markers of breast cancer. Br. J. Cancer 2002, 86, 1440-1443.
85. Fowler, L. J., Lovell, M. O., Izbicka, E., Fine-needle aspiration in PreservCyt: A novel and reproducible method for possible ancillary proteomic pattern expression of breast neoplasms by SELDI-TOF. Mod. Pathol. 2004, 17, 1012-1020.
86. Coombes, K. R., Fritsche, H. A., Jr., Clarke, C., Chen, J. N. et al., Quality control and peak finding for proteomics data collected from nipple aspirate fluid by surface-enhanced laser desorption and ionization. Clin. Chem. 2003, 49, 1615-1623.
87. Sauter, E. R., Shan, S., Hewett, J. E., Speckman, P., Du Bois, G. C., Proteomic analysis of nipple aspirate fluid using SELDI-TOF-MS. Int. J. Cancer 2005, 114, 791-796.
88. Li, J., Zhao, J., Yu, X., Lange, J. et al., Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid. Clin. Cancer Res. 2005, 11, 8312-8320.
89. Pawlik, T. M., Fritsche, H., Coombes, K. R., Xiao, L. et al., Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry. Breast Cancer Res. Treat. 2005, 89, 149-157.
90. Kuerer, H. M., Coombes, K. R., Chen, J. N., Xiao, L. et al., Association between ductal fluid proteomic expression profiles and the presence of lymph node metastases in women with breast cancer. Surgery 2004, 136, 1061-1069.
91. Traub, F., Feist, H., Kreipe, H. H., Pich, A., SELDI-MS-based expression profiling of ductal invasive and lobular invasive human breast carcinomas. Pathol. Res. Pract. 2005, 201, 763-770.
92. Streckfus, C. F., Bigler, L. R., Zwick, M., The use of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to detect putative breast cancer markers in saliva: A feasibility study. J. Oral Pathol. Med. 2006, 35, 292-300.
93. Ricolleau, G., Charbonnel, C., Lode, L., Loussouarn, D. et al., Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors. Proteomics 2006, 6, 1963-1975.
94. Goncalves, A., Esterni, B., Bertucci, F., Sauvan, R. et al., Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy. Oncogene 2006, 25, 981-989.
95. Laronga, C., Becker, S., Watson, P., Gregory, B. et al., SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers. Dis. Markers 2003, 19, 229-238.
96. Heike, Y., Hosokawa, M., Osumi, S., Fujii, D. et al., Identification of serum proteins related to adverse effects induced by docetaxel infusion from protein expression profiles of serum using SELDI ProteinChip system. Anticancer Res. 2005, 25, 1197-1203.
97. Pusztai, L., Gregory, B. W., Baggerly, K. A., Peng, B. et al., Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer 2004, 100, 1814-1822.
98. Villanueva, J., Shaffer, D. R., Philip, J., Chaparro, C. A. et al., Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest. 2006, 116, 271-284.
99. de Noo, M. E., Deelder, A., van der Werff, M., Ozalp, A. et al., MALDI-TOF serum protein profiling for the detection of breast cancer. Onkologie 2006, 29, 501-506.
100. Shin, S., Cazares, L., Schneider, H., Mitchell, S. et al., Serum biomarkers to differentiate benign and malignant mammographic lesions. J. Am. Coll. Surg. 2007, 204, 1065-1071; discussion 1071-1063.
101. Alexander, H., Stegner, A. L., Wagner-Mann, C., Du Bois, G. C. et al., Proteomic analysis to identify breast cancer biomarkers in nipple aspirate fluid. Clin. Cancer Res. 2004, 10, 7500-7510.
102. Dekker, L. J., Boogerd, W., Stockhammer, G., Dalebout, J. C. et al., MALDI-TOF mass spectrometry analysis of cerebrospinal fluid tryptic peptide profiles to diagnose leptomeningeal metastases in patients with breast cancer. Mol. Cell. Proteomics 2005, 4, 1341-1349.
103. Caldwell, R. L., Caprioli, R. M., Tissue profiling by mass spectrometry: A review of methodology and applications. Mol. Cell. Proteomics 2005, 4, 394-401.
104. Chaurand, P., Schwartz, S. A., Reyzer, M. L., Caprioli, R. M., Imaging mass spectrometry: Principles and potentials. Toxicol. Pathol. 2005, 33, 92-101.
105. Reyzer, M. L., Caprioli, R. M., MALDI mass spectrometry for direct tissue analysis: A new tool for biomarker discovery. J. Proteome Res. 2005, 4, 1138-1142.
106. Finlay, E. M., Games, D. E., Startin, J. R., Gilbert, J., Screening, confirmation, and quantification of sulphonamide residues in pig kidney by tandem mass spectrometry of crude extracts. Biomed. Environ. Mass Spectrom. 1986, 13, 633-639.
107. Phillips, W. H., Jr., Ota, K., Wade, N. A., Tandem mass spectrometry (MS/ MS) utilizing electron impact ionization and multiple reaction monitoring for the rapid, sensitive, and specific identification and quantitation of morphine in whole blood. J. Anal. Toxicol. 1989, 13, 268-273.
108. Anderson, L., Hunter, C. L., Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell. Proteomics 2006, 5, 573-588.
109. Keshishian, H., Addona, T., Burgess, M., Kuhn, E., Carr, S. A., Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol. Cell. Proteomics 2007, 6, 2212-2229.
110. Sleno, L., Volmer, D. A., Some fundamental and technical aspects of the quantitative analysis of pharmaceutical drugs by matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun. Mass Spectrom. 2005, 19, 1928-1936.
111. Volmer, D. A., Sleno, L., Bateman, K., Sturino, C. et al., Comparison of MALDI to ESI on a triple quadrupole platform for pharmacokinetic analyses. Anal. Chem. 2007, 79, 9000-9006.
112. Liotta, L. A., Petricoin, E. F., Serum peptidome for cancer detection: Spinning biologic trash into diagnostic gold. J. Clin. Invest. 2006, 116, 26-30.
113. Hu, S., Yu, T., Xie, Y., Yang, Y. et al., Discovery of oral fluid biomarkers for human oral cancer by mass spectrometry. Cancer Genomics Proteomics 2007, 4, 55-64.
114. Ward, D. G., Roberts, K., Brookes, M. J., Joy, H. et al., Increased hepcidin expression in colorectal carcinogenesis. World J. Gastroenterol. 2008, 14, 1339-1345.
115. M'Koma, A. E., Blum, D. L., Norris, J. L., Koyama, T. et al., Detection of preneoplastic and neoplastic prostate disease by MALDI profiling of urine. Biochem. Biophys. Res. Commun. 2007, 353, 829-834.
116. Fiedler, G. M., Baumann, S., Leichtle, A., Oltmann, A. et al., Standardized peptidome profiling of human urine by magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin. Chem. 2007, 53, 421-428.
117. Goufman, E. I., Moshkovskii, S. A., Tikhonova, O. V., Lokhov, P. G. et al., Two-dimensional electrophoretic proteome study of serum thermostable fraction from patients with various tumor conditions. Biochemistry (Moscow) 2006, 71, 354-360.
118. Villanueva, J., Martorella, A. J., Lawlor, K., Philip, J. et al., Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age. Mol. Cell. Proteomics 2006, 5, 1840-1852.
119. Villanueva, J., Nazarian, A., Lawlor, K., Yi, S. S. et al., A sequence-specific exopeptidase activity test (SSEAT) for "functional" biomarker discovery. Mol. Cell. Proteomics 2008, 7, 509-518.
120. de Noo, M. E., Mertens, B. J., Ozalp, A., Bladergroen, M. R. et al., Detection of colorectal cancer using MALDI-TOF serum protein profiling. Eur. J. Cancer 2006, 42, 1068-1076.
121. Callesen, A. K., Mohammed, S., Bunkenborg, J., Kruse, T. A. et al., Serum protein profiling by miniaturized solid-phase extraction and matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun. Mass Spectrom. 2005, 19, 1578-1586.
122. Ebert, M. P., Niemeyer, D., Deininger, S. O., Wex, T. et al., Identification and confirmation of increased fibrinopeptide a serum protein levels in gastric cancer sera by magnet bead assisted MALDI-TOF mass spectrometry. J. Proteome Res. 2006, 5, 2152-2158.
123. Gericke, B., Raila, J., Sehouli, J., Haebel, S. et al., Micro-heterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients. BMC Cancer 2005, 5, 133.
124. Liu, C., Shea, N., Rucker, S., Harvey, L. et al., Proteomic patterns for classification of ovarian cancer and CTCL serum samples utilizing peak pairs indicative of post-translational modifications. Proteomics 2007, 7, 4045-4052.
125. Lopez, M. F., Mikulskis, A., Kuzdzal, S., Golenko, E. et al., A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. Clin. Chem. 2007, 53, 1067-1074.
126. Chang, J. T., Chen, L. C., Wei, S. Y., Chen, Y. J. et al., Increase diagnostic efficacy by combined use of fingerprint markers in mass spectrometry-plasma peptidomes from nasopharyngeal cancer patients for example. Clin. Biochem. 2006, 39, 1144-1151.
127. Zhang, X., Leung, S. M., Morris, C. R., Shigenaga, M. K., Evaluation of a novel, integrated approach using functionalized magnetic beads, bench-top MALDI-TOF-MS with prestructured sample supports, and pattern recognition software for profiling potential biomarkers in human plasma. J. Biomol. Technol. 2004, 15, 167-175.
128. Huang, C. M., Ananthaswamy, H. N., Barnes, S., Ma, Y. et al., Mass spectrometric proteomics profiles of in vivo tumor secretomes: Capillary ultrafiltration sampling of regressive tumor masses. Proteomics 2006, 6, 6107-6116.
129. Ryu, O. H., Atkinson, J. C., Hoehn, G. T., Illei, G. G., Hart, T. C., Identification of parotid salivary biomarkers in Sjogren's syndrome by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry and two-dimensional difference gel electrophoresis. Rheumatology (Oxford) 2006, 45, 1077-1086.
130. Imanguli, M. M., Atkinson, J. C., Harvey, K. E., Hoehn, G. T. et al., Changes in salivary proteome following allogeneic hematopoietic stem cell transplantation. Exp. Hematol. 2007, 35, 184-192.
131. Munro, N. P., Cairns, D. A., Clarke, P., Rogers, M. et al., Urinary biomarker profiling in transitional cell carcinoma. Int. J. Cancer 2006, 119, 2642-2650.
132. Rogers, M. A., Clarke, P., Noble, J., Munro, N. P. et al., Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: Identification of key issues affecting potential clinical utility. Cancer Res. 2003, 63, 6971-6983.
133. Kemna, E. H., Tjalsma, H., Podust, V. N., Swinkels, D. W., Mass spectrometry-based hepcidin measurements in serum and urine: Analytical aspects and clinical implications. Clin. Chem. 2007, 53, 620-628.
134. Ye, B., Skates, S., Mok, S. C., Horick, N. K. et al., Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin. Cancer Res. 2006, 12, 432-441.
135. Suzuki, M., Ross, G. F., Wiers, K., Nelson, S. et al., Identification of a urinary proteomic signature for lupus nephritis in children. Pediatr. Nephrol. 2007, 22, 2047-2057.
136. Dihazi, H., Muller, G. A., Lindner, S., Meyer, M. et al., Characterization of diabetic nephropathy by urinary proteomic analysis: Identification of a processed ubiquitin form as a differentially excreted protein in diabetic nephropathy patients. Clin. Chem. 2007, 53, 1636-1645.
137. Khurana, M., Traum, A. Z., Aivado, M., Wells, M. P. et al., Urine proteomic profiling of pediatric nephrotic syndrome. Pediatr. Nephrol. 2006, 21, 1257-1265.
138. Schweigert, F. J., Wirth, K., Raila, J., Characterization of the microheterogeneity of transthyretin in plasma and urine using SELDI-TOF-MS immunoassay. Proteome Sci. 2004, 2, 5.
139. Semmes, O. J., Feng, Z., Adam, B. L., Banez, L. L. et al., Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin. Chem. 2005, 51, 102-112.
140. Albrethsen, J., Bogebo, R., Gammeltoft, S., Olsen, J. et al., Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP 1-3) in colon cancer serum and tumours: A biomarker study. BMC Cancer 2005, 5, 8.
141. Engwegen, J. Y., Helgason, H. H., Cats, A., Harris, N. et al., Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J. Gastroenterol. 2006, 12, 1536-1544.
142. Ren, H., Du, N., Liu, G., Hu, H. T. et al., Analysis of variabilities of serum proteomic spectra in patients with gastric cancer before and after operation. World J. Gastroenterol. 2006, 12, 2789-2792.
143. Smith, F. M., Gallagher, W. M., Fox, E., Stephens, R. B. et al., Combination of SELDI-TOF-MS and data mining provides early-stage response prediction for rectal tumors undergoing multimodal neoadjuvant therapy. Ann. Surg. 2007, 245, 259-266.
144. Ward, D. G., Suggett, N., Cheng, Y., Wei, W. et al., Identification of serum biomarkers for colon cancer by proteomic analysis. Br. J. Cancer 2006, 94, 1898-1905.
145. Tomosugi, N., Kawabata, H., Wakatabe, R., Higuchi, M. et al., Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood 2006, 108, 1381-1387.
146. Ye, B., Cramer, D. W., Skates, S. J., Gygi, S. P. et al., Haptoglobin-α subunit as potential serum biomarker in ovarian cancer: Identification and characterization using proteomic profiling and mass spectrometry. Clin. Cancer Res. 2003, 9, 2904-2911.
147. Zhang, Z., Bast, R. C., Jr., Yu, Y., Li, J. et al., Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004, 64, 5882-5890.
148. Helleman, J., van der Vlies, D., Jansen, M. P., Luider, T. M. et al., Serum proteomic patterns for ovarian cancer monitoring. Int. J. Gynecol. Cancer 2007, 18, 985-995.
149. Yu, J. K., Zheng, S., Tang, Y., Li, L., An integrated approach utilizing proteomics and bioinformatics to detect ovarian cancer. J. Zhejiang Univ. Sci. B 2005, 6, 227-231.
150. Kong, F., Nicole White, C., Xiao, X., Feng, Y. et al., Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer. Gynecol. Oncol. 2006, 100, 247-253.
151. Kozak, K. R., Amneus, M. W., Pusey, S. M., Su, F. et al., Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: Potential use in diagnosis and prognosis. Proc. Natl. Acad. Sci. USA 2003, 100, 12343-12348.
152. Rai, A. J., Zhang, Z., Rosenzweig, J., Shih Ie, M. et al., Proteomic approaches to tumor marker discovery. Arch. Pathol. Lab. Med. 2002, 126, 1518-1526.
153. Zhang, H., Kong, B., Qu, X., Jia, L. et al., Biomarker discovery for ovarian cancer using SELDI-TOF-MS. Gynecol. Oncol. 2006, 102, 61-66.
154. Berger, J. R., Avison, M., Mootoor, Y., Beach, C., Cerebrospinal fluid proteomics and human immunodeficiency virus dementia: Preliminary observations. J. Neurovirol. 2005, 11, 557-562.
155. Tolson, J., Bogumil, R., Brunst, E., Beck, H. et al., Serum protein profiling by SELDI mass spectrometry: Detection of multiple variants of serum amyloid α in renal cancer patients. Lab. Invest. 2004, 84, 845-856.
156. Wu, S. P., Lin, Y. W., Lai, H. C., Chu, T. Y. et al., SELDI-TOF MS profiling of plasma proteins in ovarian cancer. Taiwan J. Obstet. Gynecol. 2006, 45, 26-32.
157. Svensson, A. M., Whiteley, G. R., Callas, P. W., Bovill, E. G., SELDI-TOF plasma profiles distinguish individuals in a protein C-deficient family with thrombotic episodes occurring before age 40. Thromb. Haemost. 2006, 96, 725-730.
158. Ward, D. G., Wei, W., Cheng, Y., Billingham, L. J. et al., Plasma proteome analysis reveals the geographical origin and liver tumor status of Dab (Limanda limanda) from UK marine waters. Environ. Sci. Technol. 2006, 40, 4031-4036.
159. Lin, Y. W., Lin, C. Y., Lai, H. C., Chiou, J. Y. et al., Plasma proteomic pattern as biomarkers for ovarian cancer. Int. J. Gynecol. Cancer 2006, 16, 139-146.
160. Abdul-Salam, V. B., Paul, G. A., Ali, J. O., Gibbs, S. R. et al., Identification of plasma protein biomarkers associated with idiopathic pulmonary arterial hypertension. Proteomics 2006, 6, 2286-2294.
161. Moshkovskii, S. A., Serebryakova, M. V., Kuteykin-Teplyakov, K. B., Tikhonova, O. V. et al., Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1. Proteomics 2005, 5, 3790-3797.
162. Rai, A. J., Stemmer, P. M., Zhang, Z., Adam, B. L. et al., Analysis of human proteome organization plasma proteome project (HUPO PPP) reference specimens using surface enhanced laser desorption/ ionization-time of flight (SELDI-TOF) mass spectrometry: Multi-institution correlation of spectra and identification of biomarkers. Proteomics 2005, 5, 3467-3474.
163. Wilson, A. M., Kimura, E., Harada, R. K., Nair, N. et al., β2-microglobulin as a biomarker in peripheral arterial disease: Proteomic profiling and clinical studies. Circulation 2007, 116, 1396-1403.
164. Murphy, V. E., Johnson, R. F., Wang, Y. C., Akinsanya, K. et al., Proteomic study of plasma proteins in pregnant women with asthma. Respirology 2006, 11, 41-48.
165. Noble, J. L., Dua, R. S., Coulton, G. R., Isacke, C. M., Gui, G. P., A comparative proteinomic analysis of nipple aspiration fluid from healthy women and women with breast cancer. Eur. J. Cancer 2007, 43, 2315-2320.
166. Khwaja, F. W., Nolen, J. D., Mendrinos, S. E., Lewis, M. M. et al., Proteomic analysis of cerebrospinal fluid discriminates malignant and nonmalignant disease of the central nervous system and identifies specific protein markers. Proteomics 2006, 6, 6277-6287.
167. Pasinetti, G. M., Ungar, L. H., Lange, D. J., Yemul, S. et al., Identification of potential CSF biomarkers in ALS. Neurology 2006, 66, 1218-1222.
168. Ranganathan, S., Williams, E., Ganchev, P., Gopalakrishnan, V. et al., Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J. Neurochem. 2005, 95, 1461-1471.
169. Gineste, C., Ho, L., Pompl, P., Bianchi, M., Pasinetti, G. M., High-throughput proteomics and protein biomarker discovery in an experimental model of inflammatory hyperalgesia: Effects of nimesulide. Drugs 2003, 63, 23-29.
170. Feuerstein, I., Rainer, M., Bernardo, K., Stecher, G. et al., Derivatized cellulose combined with MALDI-TOF MS: A new tool for serum protein profiling. J. Proteome Res. 2005, 4, 2320-2326.
171. Feuerstein, I., Najam-ul-Haq, M., Rainer, M., Trojer, L. et al., Material-enhanced laser desorption/ionization (MELDI)-A new protein profiling tool utilizing specific carrier materials for time of flight mass spectrometric analysis. J. Am. Soc. Mass Spectrom. 2006, 17, 1203-1208.
172. Boernsen, K. O., Gatzek, S., Imbert, G., Controlled protein precipitation in combination with chip-based nanospray infusion mass spectrometry: An approach for metabolomics profiling of plasma. Anal. Chem. 2005, 77, 7255-7264.
173. Wang, H., Clouthier, S. G., Galchev, V., Misek, D. E. et al., Intact-protein-based high-resolution three-dimensional quantitative analysis system for proteome profiling of biological fluids. Mol. Cell. Proteomics 2005, 4, 618-625.